Press Releases June 5, 2026 09:24 PM

InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering

InterPrivate Investment Partners V, Inc. completes $201.25 million IPO on Nasdaq to fund future business combination.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
IPVVU

InterPrivate Investment Partners V, Inc., a blank check company focused on mergers and acquisitions, has closed its initial public offering of 20,125,000 units at $10 per unit, raising $201.25 million before expenses. The units began trading on Nasdaq under the ticker symbol IPVVU, with plans to list their Class A shares and warrants separately in the future. The company aims to leverage its leadership's private equity, technology, and digital assets expertise to identify a high-quality business for a future combination.

InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering
IPVVU
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Raised $201.25 million through IPO with 20,125,000 units sold at $10 each.
  • Units trade on Nasdaq under symbol IPVVU, with plans for separate listing of shares (IPVV) and warrants (IPVVW).
  • Company led by experienced management targeting mergers with businesses benefiting from public market access, focusing on sectors like technology and digital assets.

New York, NY, June 05, 2026 (GLOBE NEWSWIRE) -- InterPrivate Investment Partners V, Inc. (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced the closing of its initial public offering of 20,125,000 units, including 2,625,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full, at a price of $10.00 per unit on June 5, 2026. Total gross proceeds from the offering were $201.25 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

The units began trading on The Nasdaq Global Market (“Nasdaq”) under the ticker symbol “IPVVU” on June 4, 2026. Each unit consists of one Class A ordinary share of the Company and one-third of one redeemable public warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq under the symbols “IPVV” and “IPVVW,” respectively.

Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering. EarlyBirdCapital, Inc. acted as co-manager.

The public offering was made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, New York, New York 10022, Attention: General Counsel, or by email at: [email protected]

A registration statement relating to the securities became effective on June 3, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About InterPrivate Investment Partners V, Inc.

InterPrivate Investment Partners V, Inc. is a blank check company organized for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company is controlled by affiliates of Ahmed M. Fattouh, Chairman and Chief Executive Officer, and is also led by Lex Sokolin, President; Brandon Bentley, General Counsel; Dimitri Goulandris and Nick Krenteras, Directors. The Company intends to leverage its management team’s broad experience and relationships across private equity, technology and digital assets to identify and consummate an initial business combination with a high-quality target business that can benefit from access to the public capital markets and from the experience, relationships and execution capabilities of its sponsor and management team. The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the anticipated use of the net proceeds from the offering. No assurance can be given that the net proceeds of the offering will be used as indicated, or that the Company will ultimately complete a business combination transaction. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the Company’s offering filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

InterPrivate Investment Partners V, Inc.
Brandon Bentley
[email protected]
[email protected]
www.interprivate.com


Risks

  • No assurance the company will complete a business combination transaction, posing execution risk.
  • Forward-looking statements subject to market and regulatory risks detailed in the company's SEC filings.
  • As a blank check (SPAC) company, investment depends on identifying a suitable target and market conditions, which are uncertain.

More from Press Releases

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026 Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems Jun 5, 2026 Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study Jun 5, 2026 Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026 Jun 5, 2026 B2Gold Announces Voting Results from its 2026 Annual General and Special Meeting Jun 5, 2026